Since the start of the pandemic, dermatologists have seen an average 50% drop in patient volume. While teledermatology has offered a channel for non-urgent patients and patient visits are rebounding, overall patient volumes are still significantly lower than 2019.
A cross-sectional study revealed an increase and heightened prevalence of Demodex and demodicosis in individuals with psoriasis receiving biologic therapy.
Researchers conducted a population-based study examining a sample of patients with HS during hospital admissions.
Linda Stein-Gold, MD, and Michael Cameron, MD, FAAD, discuss the need for non-steroidal treatment options in atopic dermatitis management, driven by patient preferences. They highlight…
Desai emphasized that most dermatologists would rather biopsy a potential melanoma than miss one that could become deadly.
In online discussion April 23,commissioners cited health care specifically among their reasons for supporting the ban.
A review found that Mohs micrographic surgery and conventional excision yielded comparable patient reported outcomes.
At present, deployed members of the military are not permitted to be receiving therapy with systemic therapies such as immunomodulators and biologics.
In LEVEL-UP, upadacitinib demonstrated superiority over dupilumab in achieving EASI-90 and little to no itch at week 16.
Posters from the Academy of Managed Care Pharmacy annual meeting featured studies on atopic dermatitis.
Sixty percent of dupilumab-treated patients with AD treated with 400mg of eblasakimab weekly achieved EASI-90 after 16 weeks.
